Peptides for Perimenopause: What's Actually Worth Trying

Perimenopause typically begins in a woman's early to mid-40s, though it can start as early as the late 30s. It is not a single event. It is a 4- to 10-year transition during which estrogen, progesterone, and other hormones fluctuate unpredictably before declining to postmenopausal levels. The symptoms are systemic: hot flashes, sleep disruption, mood changes, brain fog, weight redistribution, accelerated skin aging, joint pain, and fatigue.

Hormone replacement therapy (HRT) addresses the estrogen and progesterone deficiency directly and remains the most evidence-supported treatment for vasomotor symptoms and bone protection. But HRT does not address every axis that shifts during perimenopause. Growth hormone declines independently of sex hormones. Collagen production drops. Inflammatory markers rise. Gut function changes. Mitochondrial efficiency declines.

This is where peptides enter the conversation. Not as a replacement for HRT, but as targeted interventions for the parallel axes that sex hormone replacement does not cover.

What Is Actually Happening in Perimenopause

The hormonal shifts of perimenopause extend far beyond estrogen. Growth hormone secretion, already declining since age 25, accelerates its drop. IGF-1 levels fall. NAD+ levels decrease, impairing mitochondrial energy production. Collagen synthesis drops approximately 30 percent in the first five years after menopause. Inflammatory markers including CRP and IL-6 rise as estrogen's anti-inflammatory effects wane.

These parallel declines explain why perimenopausal women often describe feeling as though everything is deteriorating simultaneously. It is not one system failing. It is multiple systems losing their hormonal support structures at the same time.

HRT and Peptides: Not Either/Or

HRT (estradiol, progesterone, and sometimes testosterone) is the foundation. It addresses the primary deficiency and has strong evidence for symptom relief, cardiovascular protection (when started early), and bone preservation. If you are a candidate for HRT and your symptoms warrant it, peptides are not a substitute.

But HRT does not restore growth hormone. It does not directly upregulate collagen synthesis beyond what estrogen replacement provides. It does not address gut inflammation or mitochondrial decline. Peptides can target these specific gaps.

GLP-1s for Perimenopausal Weight and Metabolism

The metabolic shift in perimenopause is one of the most frustrating symptoms. As estrogen declines, insulin sensitivity worsens and visceral fat accumulation increases, even in women who have never struggled with weight. Fat redistributes from hips and thighs to the abdomen, driven by changes in adipocyte estrogen receptor expression.

GLP-1 receptor agonists address this shift at the metabolic level. Semaglutide and tirzepatide improve insulin sensitivity, reduce visceral fat specifically, and produce meaningful weight loss. For women in perimenopause who are experiencing metabolic changes resistant to diet and exercise, GLP-1 therapy targets the underlying insulin resistance rather than just reducing caloric intake.

Orforglipron (Foundayo), the oral GLP-1 approved in April 2026, offers a needle-free option that may be more appealing for women not comfortable with injections.

GHK-Cu for Collagen and Skin

Collagen production drops approximately 30 percent in the first five years after menopause, driven by estrogen decline. While HRT partially restores collagen synthesis through estrogen receptor activation in fibroblasts, the copper peptide GHK-Cu offers a complementary mechanism.

GHK-Cu stimulates collagen I and III synthesis, increases elastin production, promotes glycosaminoglycan synthesis, and supports wound healing. It also increases SOD (superoxide dismutase) activity, providing antioxidant protection for skin cells. Studies show improvements in skin thickness, elasticity, and firmness with topical and injectable GHK-Cu.

For perimenopausal women, GHK-Cu addresses the collagen decline from a different angle than estrogen. It activates the tissue remodeling genes that maintain skin structure, making it a logical complement to HRT for skin aging.

DSIP and Selank for Sleep and Mood

Sleep disruption is one of the earliest and most persistent perimenopausal symptoms. Hot flashes wake women from sleep, but even without vasomotor symptoms, sleep architecture changes. Slow-wave sleep decreases, sleep latency increases, and sleep efficiency drops.

DSIP (delta sleep-inducing peptide) promotes slow-wave sleep through modulation of serotonin and GABA pathways. It does not act as a sedative in the traditional sense. Instead, it appears to facilitate natural sleep architecture. Selank, a synthetic peptide based on tuftsin, has anxiolytic properties that may help with the mood and anxiety changes that frequently accompany perimenopause.

Both peptides are on the July 23-24 PCAC docket. DSIP's nominated indication is sleep disorders, and Semax (related to Selank in the nootropic category) is nominated for cognitive enhancement.

BPC-157 for Joint and Tissue Integrity

Joint pain is a surprisingly common perimenopausal symptom. Estrogen has anti-inflammatory effects on joints, and its decline can trigger or worsen arthralgias. Tendons, ligaments, and cartilage also lose structural integrity as collagen declines.

BPC-157 promotes tendon, ligament, and muscle healing through angiogenesis and growth factor modulation. It also has anti-inflammatory properties in the gut. For perimenopausal women experiencing joint stiffness, tendon issues, or gut-related symptoms alongside their hormonal transition, BPC-157 addresses the tissue-repair axis that HRT does not directly target.

CJC-1295/Ipamorelin for GH Optimization

Growth hormone secretion declines approximately 14 percent per decade after age 25. By perimenopause, GH levels are often significantly below youthful baselines. Low GH contributes to decreased lean muscle mass, increased body fat, reduced skin thickness, impaired recovery, and diminished sleep quality.

CJC-1295 (a GHRH analog) paired with Ipamorelin (a ghrelin receptor agonist) stimulates pulsatile GH release that mimics natural secretion patterns. Unlike exogenous GH, these peptides work through the body's own regulatory feedback, reducing the risk of supraphysiological GH levels.

For perimenopausal women, GH optimization may support body composition, sleep quality, and tissue recovery. However, GH secretagogues should be used under medical supervision, as GH affects glucose metabolism and may interact with the metabolic changes of perimenopause.

The Honest Assessment

Not every peptide mentioned above has robust human clinical trial data specifically in perimenopausal women. GLP-1 RAs have the strongest evidence base. GHK-Cu has solid skin-specific data. BPC-157 and GH secretagogues have extensive preclinical and anecdotal clinical evidence but fewer formal trials in this specific population.

The honest framing is this: perimenopause involves multiple simultaneous hormonal declines. HRT addresses the primary one. Peptides offer mechanistically targeted options for the others. The evidence varies by compound, and the best approach is to work with a provider who understands both HRT and peptide therapy.